Methods for treating IgE-mediated disorder
This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods of making IgD, as well as methods of screening for antimicrobial agents from IgD-activated basophils.
1. A method of attenuating an IgE-mediated response from basophils in a subject having an IgE-mediated disorder, comprising administering to said subject an unconjugated anti-IgD antibody that causes cross-linking of IgD pre-bound to the surface of said basophils to attenuate said IgE-mediated response from basophils thereby treating said IgE-mediated disorder.
2. The method of claim 1 , wherein said IgE-mediated response is histamine release.
3. The method of claim 1 , wherein said unconjugated anti-IgD antibody is a monoclonal antibody.
4. The method of claim 1 , wherein said unconjugated anti-IgD antibody is a polyclonal antibody.
5. The method of claim 1 , wherein said IgE-mediated disorder is selected from the group consisting of asthma, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, eczema, urticaria, food allergy and seasonal allergy.
6. The method of claim 1 , wherein said unconjugated anti-IgD antibody is administered by injections, inhalations, ingestions or implantations.
7. The method of claim 1 , wherein said unconjugated anti-IgD antibody is a deimmunized antibody.
8. The method of claim 1 , wherein said unconjugated anti-IgD antibody is a multivalent antibody fragment.